Press Releases
AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections
Patent allowed by the USPTO that includes claims for niclosamide as a treatment for COVID-19 GI…
AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections
DELRAY BEACH, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or…
FirstWave Bio to Initiate Phase 2a/2b Study of FW-1022, a Proprietary Form of Niclosamide, to Treat COVID-19
Proprietary formulation of approved antiviral medicine targets viral “reservoir” in the gut believed responsible for prolonged…